摘要
卵巢癌因早期症状隐匿,缺乏有效可靠的生物学指标,且对化疗具有明显的耐药性,故死亡率较高。寻找灵敏性高、特异性好的生物标志物是现代卵巢肿瘤研究的主要方向。人激肽释放酶相关肽酶(KLK)家族参与癌细胞的增殖、侵袭、转移及血管生成等过程,且与恶性肿瘤的预后相关,并促进疾病的发生和发展。KLK复杂的表达调控机制及其亚型在卵巢癌的诊断、治疗、预后及耐药性等方面具有重要价值。此外,KLK在肿瘤微环境下对卵巢癌进展也起关键作用,深入研究KLK蛋白质水解网络与卵巢癌肿瘤微环境相互作用的机制可能能为寻找卵巢癌新的治疗靶点提供依据。
Ovarian cancer has high mortality due to its occult early symptoms,lack of effective and reliable biological indicators,and obvious drug resistance to chemotherapy. Looking for biomarkers with high sensitivity and good specificity is the main direction of modern ovarian tumor research. In recent years,it has been found that human kallikrein-related peptidase( KLK)family is involved in the proliferation,invasion,metastasis and angiogenesis of cancer cells,related to the prognosis of malignant tumors,and promotes the occurrence and development of diseases. KLK complex expression regulation mechanism and its subtypes have great value in the diagnosis,treatment,prognosis and drug resistance of ovarian cancer. In addition,KLK also play a key role in the tumor microenvironment for ovarian cancer progression. Further study on the interaction mechanism between KLK proteolytic network and tumor microenvironment of ovarian cancer may provide references to find new therapeutic targets.
作者
何征秦
王雪
蔡雪
张广美
HE Zhengqin;WANG Xue;CAI Xue;ZHANG Guangmei(Department of Gynecology and Obstetrics,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《医学综述》
CAS
2021年第10期1945-1949,共5页
Medical Recapitulate
关键词
卵巢癌
人激肽释放酶相关肽酶
肿瘤微环境
化疗耐药
Ovarian cancer
Human kallikrein-related peptidases
Tumor microenvironment
Chemotherapy resistance
